AB9598
Anti-Glial fibrillary acidic protein δ Antibody
serum, Chemicon®
Synonym(s):
GFAPdelta
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
should not react with
mouse, rat
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... GFAP(2670)
General description
Human Glial Fibrillary Acidic Protein delta (GFAP-delta) is a GFAP protein isoform that is encoded by an alternative splice variant of the GFAP-gene. As a result, GFAP-delta protein differs from the predominant splice form, GFAP-alpha, by its C-terminal protein sequence. GFAP-delta protein is not expressed by all GFAP expressing astrocytes but specifically by a subpopulation located in the subpial zone of the cerebral cortex, the subgranular zone of the hippocampus and, most intensely, by a ribbon of astrocytes following the ependymal layer of the cerebral ventricles. Therefore, at least in the sub ventricular zone (SVZ), GFAP-delta specifically marks the population of astrocytes that contain the neural stem cells in the adult human brain. Interestingly, the SVZ astrocytes actively splice GFAP-delta transcripts, in contrast to astrocytes adjacent to this layer. Data shows that GFAP-delta protein, unlike GFAP-alpha, is not upregulated in astrogliosis. Data indicates a different functional role for GFAP-delta in astrocyte physiology. Transfection studies showed that GFAP-delta protein expression has a negative effect on GFAP filament formation, and therefore could be important for modulating intermediate filament cytoskeletal properties, possibly facilitating astrocyte motility. Further studies on GFAP-delta and the cells that express it are important for gaining insights into its function during differentiation, migration and during health and disease (Roelofs, RF, et al., Glia (2005) 52:289-300.).
Specificity
Glial Fibrillary Acidic Protein-delta (GFAP-delta). The antibody does not recognize GFAP-alpha protein.
Immunogen
Synthetic peptide from human GFAP-delta.
Application
Anti-Glial fibrillary acidic protein δ Antibody is an antibody against Glial fibrillary acidic protein δ for use in WB, IH(P).
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neuronal & Glial Markers
Neuronal & Glial Markers
Western blot: 1:500 with overnight incubation. The antibody recognizes the ~60 kDa GFAP-delta protein.
Immunohistochemistry: 1:500 incubated for 36-48 hours at 2-8°C on paraffin embedded tissue sections. It is suggested that the tissue be treated with microwave antigen retrieval prior to staining.
Optimal working dilutions must be determined by the end user.
Immunohistochemistry: 1:500 incubated for 36-48 hours at 2-8°C on paraffin embedded tissue sections. It is suggested that the tissue be treated with microwave antigen retrieval prior to staining.
Optimal working dilutions must be determined by the end user.
Linkage
Replaces: 04-1031; 04-1062
Physical form
Rabbit serum. Liquid.
Storage and Stability
Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class
10 - Combustible liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
John W Prineas et al.
Journal of neuropathology and experimental neurology, 78(2), 140-156 (2019-01-04)
There are reports that astrocyte perivascular endfeet are damaged in some cases of multiple sclerosis (MS). This study was designed to determine the origin and outcome of astrocyte damage in acute, resolving, and inactive plaques. Ten acute plaques from 10
Mark J Swanson et al.
G3 (Bethesda, Md.), 13(8) (2023-03-18)
Alzheimer's disease (AD) is an age-related disorder that results in progressive cognitive impairment and memory loss. Deposition of amyloid β (Aβ) peptides in senile plaques is a hallmark of AD. γ-secretase produces Aβ peptides, mostly as the soluble Aβ40 with
Sara Cipriani et al.
Cerebral cortex (New York, N.Y. : 1991), 28(7), 2458-2478 (2018-05-04)
Neuropathological conditions might affect adult granulogenesis in the adult human dentate gyrus. However, radial glial cells (RGCs) have not been well characterized during human development and aging. We have previously described progenitor and neuronal layer establishment in the hippocampal pyramidal
Benjamin R Smith et al.
The Journal of pathology, 232(5), 509-521 (2014-01-15)
Demyelination is a major contributor to the general decay of neural functions in children with Krabbe disease. However, recent reports have indicated a significant involvement of neurons and axons in the neuropathology of the disease. In this study, we have
Hyung Woo Park et al.
Scientific reports, 10(1), 9572-9572 (2020-06-14)
Parkinson's disease is a neurodegenerative disorder, and no treatment has been yet established to prevent disease progression. Coenzyme Q10, an antioxidant, has been considered a promising neuroprotective agent; however, conventional oral administration provides limited efficacy due to its very low
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service